Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study

Table 1 Participant characteristics (n = 12)

Variable
Age [mean (range), yr]	67 (52 – 81)
Gender
Male	8 (67)
Female	4 (33)
Race
White	9 (75)
Black	3 (25)
Marital status
Married	7 (58)
Single	4 (33)
Divorced	1 (8)
Stage of cancer
PR	2 (17)
BR	7 (58)
LA	3 (25)
Location of tumor
Head	9 (75)
Body	2 (17)
Neck	1 (8)
Type of NT
Chemo	5 (42)
Chemo + XRT	7 (58)
Length of NT1
< 3 mo	1 (10)
3-6 mo	6 (60)
> 6 mo	3 (30)
Type of chemo
FOLFIRINOX	4 (33)
Gemcitabine/nab-paclitaxel	2 (17)
Other/both	6 (50)
Major complications during NT2
Hospitalization	2 (50)
ER visit, no admission	1 (25)
Other	1 (25)
Travel distance
< 15 miles	4 (33)
15 – 30 miles	1 (8)
31 – 50 miles	2 (17)
51 – 100 miles	3 (25)
100+ miles	2 (17)
Surgical resection
Yes	8 (67)
No	2 (17)
Not scheduled yet	2 (17)
Insurance status
Government	9 (75)
Private	3 (25)
Psychosocial or palliative care counseling
Yes	2 (17)
No	10 (83)

¹Values reflect the length of neoadjuvant therapy (NT) for n = 10 patients that have completed NT.

²Values for n = 4 patients that had major complications during NT.

All values are expressed as n (%) unless otherwise stated. PR: Potentially resectable; BR: Borderline resectable; LA: Locally advanced; NT: Neoadjuvant therapy.